Medical device company AtCor Medical (ASX: ACG) has today announced it has signed an agreement with a major international pharmaceutical company to supply SphygmoCor systems and clinical trials support services.
The pharmaceutical company was not named for commerciality reasons but is an existing AtCor customer.
SphygmoCor measures central blood pressures and arterial stiffness.
The value of the new agreement is US$955,000. A large portion of the contract value will be recognised in the current financial year.
“This is a significant contract, which confirms AtCor’s strong market position as the leading provider of noninvasive central blood pressure measurement in clinical trials," Duncan Ross, CEO of AtCor Medical said today.
He said the new agreement demonstrates that AtCor’s reputation for high levels of customer satisfaction is being recognised through expanded business with long-term clients.
AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease.